Guidance for central pharmacy management of clinical drug research institutions based on grade I response to major public health emergencies

ABSTRACT

Since the outbreak of pneumonia caused by severe acute vespiratory syndrome coronavirus 2. December 2019, the situation of epidemic prevention and control has become more serious. In order to strengthen the prevention and control of the epidemic and effectively prevent the spread, provinces and cities across the country have successively initiated grade I responses to major public health events. A large number of clinical trials have been obliged to suspend follow-up and group joining. Drug management is an important part of drug clinical trials. In order to actively respond to national requirements, clinical trial institutions around the country have launched a series of emergency management measures to respond to the administration of follow-up drug delivery in an epidemic situation and ensure safety of relevant researchers and participants. We hereby discuss the formulation of a central pharmacy management system for clinical trial institutions, with a view to safeguard the rights and interests of participants and ensure carrying out clinical trials safely, orderly and successfully.